Dianthus Therapeutics, Inc. DNTH
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is an immunology/inflammation drug developer. Its lead program, claseprubart (DNTH103), is in Phase 3 for CIDP (CAPTIVATE) and generalized myasthenia gravis (EMERGE). Its next catalyst on record is claseprubart: MoMeNtum Phase 2 topline (December 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: claseprubart — MoMeNtum Phase 2 topline (December 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| claseprubart | CIDP (CAPTIVATE) | antibody | Phase 3 |
| claseprubart | gMG (EMERGE) | antibody | Phase 3 |
| claseprubart | multifocal motor neuropathy (MoMeNtum) | antibody | Phase 2 |
| DNTH212 | BDCA2/BAFF | antibody | Phase 1 |
| DNTH312 | immunology | antibody | Pre-clinical |
Recent results and decisions
- Aug 4, 2026positive Interim responder analysis of first 40 participants completing Part A of Phase 3 CAPTIVATE showed a 75% response rate vs a 50% target, generally well tolerated with no related serious infections or SAEs.
75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of 50% or greater based on precedent set with aC1s inhibition.
Filing - Aug 4, 2026completed enrollment Phase 2 MoMeNtum trial in MMN completed enrollment at 46 patients, exceeding the original target of 36.
The MoMeNtum trial, a global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN, exceeded its original enrollment target of 36 patients.
Filing - Jun 30, 2026started Phase 3 EMERGE registrational trial of claseprubart in gMG (300mg Q2W and Q4W) was initiated in June 2026.
A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients was initiated in June, with top-line results expected in 2H’28.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.